Full-Time

Research Intern

Posted on 5/16/2026

GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

Compensation Overview

$45 - $57/hr

No H1B Sponsorship

Bellevue, WA, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
LLM
Python
Regression
R
Neural Networks
Machine Learning
Computer Vision
Data Analysis

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • Currently enrolled in a Bachelor’s degree in Biology, Biostatistics, Bioinformatics, or a related field
  • Strong foundation in statistics (e.g., hypothesis testing, regression, data analysis)
  • Proficiency in R and/or Python for data analysis
  • Familiarity with at least one area of machine learning concepts such as Computer Vision, Deep Learning, or Algorithmic Foundations of Optimization
  • Experience working with large datasets and data wrangling techniques
  • Ability to interpret and communicate quantitative results in a biological or clinical context
  • Strong problem-solving skills and ability to work under research supervision
Responsibilities
  • Analyze large-scale biological and healthcare datasets using statistical and computational methods
  • Apply statistical modeling techniques and, where appropriate, machine learning approaches to support research questions
  • Contribute to the design and development of machine learning models (including exposure to deep learning and LLM-based approaches) to support automation of clinical or research tasks using data such as medical images, electronic health records, waveforms, and clinical reports
  • Write and maintain code in R and/or Python for data cleaning, transformation, analysis, and visualization
  • Perform statistical validation, error estimation, and interpretation of model and analysis results across diverse datasets
  • Assist in building prototypes and reproducible workflows that support scalable, high-quality research and algorithm development
  • Collaborate with researchers to translate biological and clinical questions into quantitative analyses and data-driven solutions
  • Support the exploration and evaluation of new methodologies, tools, and technologies in data science, machine learning, and healthcare applications
  • Contribute to preparation of research outputs, including visualizations, reports, and potential publications
Desired Qualifications
  • Exposure to machine learning or AI concepts (e.g., classification, clustering, predictive modeling)
  • Familiarity with biological or clinical data types (e.g., genomics, imaging, EHR data)
  • Experience with data visualization tools (e.g., ggplot2, matplotlib, seaborn)
  • Knowledge of reproducible research practices (e.g., version control, scripting workflows)
  • Interest in contributing to research publications or presentations

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11.1% and backlog hit a record $23.9 billion.
  • August 3, 2026 Invenia ABUS Prime targets dense-breast screening demand and remote reading.
  • Tariff refunds and supply-chain shifts lifted Q2 2026 profits, while 2026 guidance stayed reaffirmed.

What critics are saying

  • Patient Care Solutions fell 13.5% in Q2 2026, and management is reviewing sale options.
  • CFO Jay Saccaro exits August 14, 2026, adding execution risk during the PCS review.
  • Siemens Healthineers and Philips pressure GEHC in imaging; stalled innovation erodes hospital preference.

What makes GE Healthcare unique

  • GE HealthCare combines imaging, pharmaceutical diagnostics, and MIM software across one workflow stack.
  • Its August 2026 ABUS Prime and Allia upgrades monetize installed bases without replacements.
  • FDA-cleared AI tools like ProtégéAI+ 2.0 shorten oncology workflows and deepen switching costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats profit estimates on imaging demand and $129M tariff refunds

GE HealthCare exceeded Wall Street's second-quarter profit estimates, driven by robust demand for diagnostic and imaging devices and tariff refunds from the Trump administration. The medical device maker reported net income of $561 million, up from $486 million last year, which included $129 million in tariff refunds. Revenue reached $5.30 billion for the quarter ending 30 June, surpassing the estimated $5.26 billion. Sales in imaging devices grew 7.9%, whilst pharmaceutical diagnostics jumped 15.6%. Adjusted earnings per share came in at $1.13, beating analysts' estimate of $1.04. The company's shares rose 12% in premarket trading. However, GE HealthCare noted that geopolitical instability, including Middle East conflicts, negatively affected costs, supply chains and logistics during the quarter.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats estimates with record orders, shares jump 9%

GE HealthCare Technologies reported second-quarter results that exceeded Wall Street expectations. Adjusted earnings per share reached $1.13, beating the $1.04 consensus estimate, whilst revenue hit $5.3 billion, surpassing the $5.26 billion forecast and marking a 5.7% year-on-year increase. The company delivered record organic orders growth of 11.1% with a book-to-bill ratio of 1.15 times and backlog of $23.9 billion. Organic revenue grew 3.5%, driven by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions. Patient Care Solutions revenue declined 13.5% year-on-year. Adjusted EBIT margin came in at 14.2%, down 40 basis points from the prior year. Shares jumped 9% premarket following the release. GE HealthCare reaffirmed its full-year guidance, projecting organic revenue growth of 3.0% to 4.0% and adjusted EPS between $4.80 and $5.00.

Fortune
Jul 23rd, 2026
GE's $593B comeback: How CEO Larry Culp pulled off history's greatest turnaround

GE CEO Larry Culp has orchestrated what many industry leaders consider the greatest corporate turnaround in modern business history. When he took over in 2018, GE's market capitalisation stood at $96 billion, down over 80% from its 2000 peak, with $150 billion in crushing debt. Today, the three companies Culp created from GE's breakup — GE Aerospace, GE Vernova, and GE HealthCare — have a combined market value of $689 billion. The trio has delivered annualised returns of roughly 30% since Culp's arrival, double the S&P 500's performance. GE Vernova has jumped over 600% whilst GE Aerospace has risen more than 160%. Culp's approach centred on lean manufacturing principles learnt from the Toyota Production System. He decentralised operations, eliminated three-quarters of central staff positions, and fostered a culture encouraging managers to spotlight problems rather than successes.

INACTIVE